Pair Name | Morin, MST312 | ||
Phytochemical Name | Morin (PubChem CID: 5281670 ) | ||
Anticancer drug Name | MST312 (PubChem CID: 10385095 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Morin, MST312 | |||
Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
Gene Regulation | Up-regulation | Phosphorylation | BAD | hsa572 |
Down-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Phosphorylation | NFKBIA | hsa4792 | |
Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
Up-regulation | Phosphorylation | TP53 | hsa7157 | |
In Vitro Model | HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
SW620 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0547 | |
Result | Our study suggests that novel targeted-therapy can be implemented by using flavonoid morin and telomerase inhibitor MST‑312 for improved cancer prognosis. |
No. | Title | Href |
---|---|---|
1 | Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol. 2016 Aug;49(2):487-98. doi: 10.3892/ijo.2016.3546. | Click |